Difference between revisions of "Profiles"
Jump to navigation
Jump to search
| Line 12: | Line 12: | ||
* [[Media:QIBA_AmyloidPET_15June2017.pdf| QIBA PET Amyloid Profile 2017-06-15]] (Public Comment Form: http://tinyurl.com/y8dy2pc2) | * [[Media:QIBA_AmyloidPET_15June2017.pdf| QIBA PET Amyloid Profile 2017-06-15]] (Public Comment Form: http://tinyurl.com/y8dy2pc2) | ||
| + | (''Public Comment is open for 90 days - until September 15, 2017'') | ||
* [[Media:QIBADWIProfilev1.45_20170427_v5_accepted_linenumbers.pdf| DWI Profile 2017-04-27]] (Public Comment Form: https://goo.gl/fkL6rB) | * [[Media:QIBADWIProfilev1.45_20170427_v5_accepted_linenumbers.pdf| DWI Profile 2017-04-27]] (Public Comment Form: https://goo.gl/fkL6rB) | ||
* [[Media:DCEMRIProfile v1 6-20111213.pdf|DCE-MRI Quantification 2011-12-13]] (''Public Comment ended Feb 2012'') | * [[Media:DCEMRIProfile v1 6-20111213.pdf|DCE-MRI Quantification 2011-12-13]] (''Public Comment ended Feb 2012'') | ||
Revision as of 21:17, 14 June 2017
Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.
Stage 3: Technically Confirmed Profiles
Stage 2: Consensus Profiles
Stage 1: Public Comment Profiles
- QIBA PET Amyloid Profile 2017-06-15 (Public Comment Form: http://tinyurl.com/y8dy2pc2)
(Public Comment is open for 90 days - until September 15, 2017)
- DWI Profile 2017-04-27 (Public Comment Form: https://goo.gl/fkL6rB)
- DCE-MRI Quantification 2011-12-13 (Public Comment ended Feb 2012)
- Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.0), October 28, 2016
Statements of Endorsement
See Also
- How to use QIBA Profiles
- Biomarker Committee pages may also have links to DRAFT Profile documents for the next Stage.
- Profile Conformance describes how sites and products claim conformance to a Profile.
- QIBA Profile Template shows the structure, rationale and content of a Profile (show "All Markup" to see guidance in the Word comments)